PCOS drug showdown: pioglitazone takes on metformin
NCT ID NCT07472179
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two diabetes drugs, pioglitazone and metformin, in 60 women with insulin-resistant PCOS. Each woman took one drug daily for three months. Researchers measured changes in insulin resistance, waist-to-hip ratio, and hormone levels to see which drug worked better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pioglitazone and metformin
- What this could lead to
- If pioglitazone works better than metformin, it could offer a new treatment option for women with insulin-resistant PCOS.
- What could go wrong
- This is a small, completed study with only 60 participants, so results may not apply to everyone. Both drugs have known side effects like weight gain or stomach issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PCOS(INSULIN RESISTANT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bangladesh Medical University
Dhaka, Shahbag, 1000, Bangladesh
More trials for these conditions
Other studies related to the condition(s) this trial covers.